Finding the Sweet Spots of Inhibition: Understanding the Targets of a Functional Antibody Against Plasmodium Vivax Duffy Binding Protein

Overview

Journal Int J Parasitol

Specialty Parasitology

Date 2012 Oct 17

PMID 23068913

Citations 11

Authors

Francis B Ntumngia

Christopher L King

John H Adams

Affiliations

Soon will be listed here.

Abstract

Plasmodium vivax Duffy binding protein region II (DBPII) is an essential ligand for reticulocyte invasion, thereby making this molecule an attractive vaccine candidate against asexual blood-stage P. vivax. Similar to other Plasmodium blood-stage vaccine candidates, strain-specific immunity due to DBPII allelic variation may complicate vaccine efficacy. Targeting immune responses to more conserved epitopes that are potential targets of strain-transcending neutralising immunity is necessary to avoid induction of strain-specific responses to dominant variant epitopes. In this article, we focus on different approaches to optimise the design of DBP immunogenicity to target conserved epitopes, which is important for developing a broadly effective vaccine against P. vivax.

Citing Articles

Preliminary characterization of Plasmodium vivax sporozoite antigens as pre-erythrocytic vaccine candidates.

Nicholas J, De S, Thawornpan P, Brashear A, Kolli S, Subramani P PLoS Negl Trop Dis. 2023; 17(9):e0011598.

PMID: 37703302 PMC: 10519608. DOI: 10.1371/journal.pntd.0011598.

Cross-reactive inhibitory antibody and memory B cell responses to variant strains of Duffy binding protein II at post-Plasmodium vivax infection.

Thawornpan P, Changrob S, Kochayoo P, Wangriatisak K, Ntumngia F, De S PLoS One. 2022; 17(10):e0276335.

PMID: 36256619 PMC: 9578595. DOI: 10.1371/journal.pone.0276335.

Global diversity and balancing selection of 23 leading Plasmodium falciparum candidate vaccine antigens.

Naung M, Martin E, Munro J, Mehra S, Guy A, Laman M PLoS Comput Biol. 2022; 18(2):e1009801.

PMID: 35108259 PMC: 8843232. DOI: 10.1371/journal.pcbi.1009801.

Multiplexed Microsphere-Based Flow Cytometric Assay to Assess Strain Transcending Antibodies to Duffy Binding Protein II Reveals an Efficient Tool to Identify Binding-Inhibitory Antibody Responders.

Alves J, de Araujo F, Pires C, Teixeira-Carvalho A, Lima B, Torres L Front Immunol. 2021; 12:704653.

PMID: 34675915 PMC: 8523986. DOI: 10.3389/fimmu.2021.704653.

Identification of an Immunogenic Broadly Inhibitory Surface Epitope of the Plasmodium vivax Duffy Binding Protein Ligand Domain.

George M, Schloegel J, Ntumngia F, Barnes S, King C, Casey J mSphere. 2019; 4(3).

PMID: 31092602 PMC: 6520440. DOI: 10.1128/mSphere.00194-19.

References

Adkins C . A new conjugate vaccine against pneumococcal disease. Nurse Pract. 2001; 26(5):52, 55-6, 59-62. DOI: 10.1097/00006205-200105000-00006. View

Ryan J, Stoute J, Amon J, Dunton R, Mtalib R, Koros J . Evidence for transmission of Plasmodium vivax among a duffy antigen negative population in Western Kenya. Am J Trop Med Hyg. 2006; 75(4):575-81. View

Mendis K, Sina B, Marchesini P, Carter R . The neglected burden of Plasmodium vivax malaria. Am J Trop Med Hyg. 2001; 64(1-2 Suppl):97-106. DOI: 10.4269/ajtmh.2001.64.97. View

Choe H, Moore M, Owens C, Wright P, Vasilieva N, Li W . Sulphated tyrosines mediate association of chemokines and Plasmodium vivax Duffy binding protein with the Duffy antigen/receptor for chemokines (DARC). Mol Microbiol. 2005; 55(5):1413-22. DOI: 10.1111/j.1365-2958.2004.04478.x. View

Wurtz N, Mint Lekweiry K, Bogreau H, Pradines B, Rogier C, Boukhary A . Vivax malaria in Mauritania includes infection of a Duffy-negative individual. Malar J. 2011; 10:336. PMC: 3228859. DOI: 10.1186/1475-2875-10-336. View

Lin E, Kiniboro B, Gray L, Dobbie S, Robinson L, Laumaea A . Differential patterns of infection and disease with P. falciparum and P. vivax in young Papua New Guinean children. PLoS One. 2010; 5(2):e9047. PMC: 2816213. DOI: 10.1371/journal.pone.0009047. View

Chackerian B . Virus-like particles: flexible platforms for vaccine development. Expert Rev Vaccines. 2007; 6(3):381-90. DOI: 10.1586/14760584.6.3.381. View

Krotoski W, Collins W, BRAY R, Garnham P, Cogswell F, Gwadz R . Demonstration of hypnozoites in sporozoite-transmitted Plasmodium vivax infection. Am J Trop Med Hyg. 1982; 31(6):1291-3. DOI: 10.4269/ajtmh.1982.31.1291. View

Welsh R, Fujinami R . Pathogenic epitopes, heterologous immunity and vaccine design. Nat Rev Microbiol. 2007; 5(7):555-63. PMC: 7097378. DOI: 10.1038/nrmicro1709. View

10.

Mendes C, Dias F, Figueiredo J, Mora V, Cano J, de Sousa B . Duffy negative antigen is no longer a barrier to Plasmodium vivax--molecular evidences from the African West Coast (Angola and Equatorial Guinea). PLoS Negl Trop Dis. 2011; 5(6):e1192. PMC: 3119644. DOI: 10.1371/journal.pntd.0001192. View

11.

Ceravolo I, Sanchez B, Sousa T, Guerra B, Soares I, Braga E . Naturally acquired inhibitory antibodies to Plasmodium vivax Duffy binding protein are short-lived and allele-specific following a single malaria infection. Clin Exp Immunol. 2009; 156(3):502-10. PMC: 2691980. DOI: 10.1111/j.1365-2249.2009.03931.x. View

12.

Chitnis C, MILLER L . Identification of the erythrocyte binding domains of Plasmodium vivax and Plasmodium knowlesi proteins involved in erythrocyte invasion. J Exp Med. 1994; 180(2):497-506. PMC: 2191600. DOI: 10.1084/jem.180.2.497. View

13.

Michon P, Cole-Tobian J, Dabod E, Schoepflin S, Igu J, Susapu M . The risk of malarial infections and disease in Papua New Guinean children. Am J Trop Med Hyg. 2007; 76(6):997-1008. PMC: 3740942. View

14.

Singh A, Ozwara H, Kocken C, Puri S, Thomas A, Chitnis C . Targeted deletion of Plasmodium knowlesi Duffy binding protein confirms its role in junction formation during invasion. Mol Microbiol. 2005; 55(6):1925-34. DOI: 10.1111/j.1365-2958.2005.04523.x. View

15.

Cole-Tobian J, Cortes A, Baisor M, Kastens W, Xainli J, Bockarie M . Age-acquired immunity to a Plasmodium vivax invasion ligand, the duffy binding protein. J Infect Dis. 2002; 186(4):531-9. DOI: 10.1086/341776. View

16.

MILLER L, Mason S, DVORAK J, McGinniss M, Rothman I . Erythrocyte receptors for (Plasmodium knowlesi) malaria: Duffy blood group determinants. Science. 1975; 189(4202):561-3. DOI: 10.1126/science.1145213. View

17.

Healer J, Murphy V, Hodder A, Masciantonio R, Gemmill A, Anders R . Allelic polymorphisms in apical membrane antigen-1 are responsible for evasion of antibody-mediated inhibition in Plasmodium falciparum. Mol Microbiol. 2004; 52(1):159-68. DOI: 10.1111/j.1365-2958.2003.03974.x. View

18.

Ranjan A, Chitnis C . Mapping regions containing binding residues within functional domains of Plasmodium vivax and Plasmodium knowlesi erythrocyte-binding proteins. Proc Natl Acad Sci U S A. 1999; 96(24):14067-72. PMC: 24191. DOI: 10.1073/pnas.96.24.14067. View

19.

Narum D, Fuhrmann S, Luu T, Sim B . A novel Plasmodium falciparum erythrocyte binding protein-2 (EBP2/BAEBL) involved in erythrocyte receptor binding. Mol Biochem Parasitol. 2002; 119(2):159-68. DOI: 10.1016/s0166-6851(01)00428-5. View

20.

Vargas-Serrato E, Barnwell J, Ingravallo P, Perler F, Galinski M . Merozoite surface protein-9 of Plasmodium vivax and related simian malaria parasites is orthologous to p101/ABRA of P. falciparum. Mol Biochem Parasitol. 2002; 120(1):41-52. DOI: 10.1016/s0166-6851(01)00433-9. View